TAVR for bicuspid aortic valve stenosis demonstrates high device success and acceptable mortality, but is associated with notable risks of paravalvular leak and pacemaker implantation.
No takes yet. Share an insight, caveat, or question.
Supports TAVR feasibility in high-risk BcAV without excess mortality; leaves open randomized confirmation of complication trade-offs versus tricuspid cohorts.
Reddy et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: